At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 9, 2026 at 06:14 ET
Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share, with a 30-day option for underwriters to purchase an additional 856,490 shares. Concurrently, argenx BV made a strategic investment in the company. The proceeds will fund clinical development and general corporate purposes.
- Forte Biosciences priced a public offering of 5,709,936 shares at $26.27 per share
- Underwriters have a 30-day option to purchase up to an additional 856,490 shares
- Gross proceeds expected to be approximately $150 million before underwriting discounts and commissions
- Net proceeds estimated at $141 million ($162 million if full option exercised), to be used for clinical development and general corporate purposes
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access